13 Aug 4Dx appoints clinical advisory board
Melbourne based medical technology start-up 4Dx has engaged the services of a Clinical Advisory Board to review and make clinical recommendations on the company’s four-dimensional lung imaging technology.
According to the company, the four-dimensional X-ray imaging technology (4DxV) provides a state-of-the-art, non-invasive way of understanding regional lung motion and airflow within the breathing lungs.
The Clinical Advisory Board consists Melbourne physicians across Radio Oncology, Molecular Imaging and Respiratory Diagnostics, who will advise on the clinical and commercial value of the technology.
Chaired by Professor Greg Snell, Head of the Lung Transplant Service at Melbourne’s Alfred Hospital, members of the Board include Professor Rod Hicks, Head of Peter Mac’s Molecular Imaging and Targeted Therapeutics Laboratory and Associate Professor Louis Irving, Director of Respiratory and Sleep Medicine and the Royal Melbourne Hospital.
The Board is facilitated by experienced medtech executive, Matt Godden who was the former Director of Medtronic’s Australasian Cardiovascular business.
Founder and Executive Chairman of 4Dx Professor Andreas Fouras said the formation of the Clinical Advisory Board is an important step in validating and refining the technology before it seeks regulatory approval for its software.
“By engaging independent medical professionals, each an expert in their own field, we have the capability to better understand the clinical applications of our core technology and appreciate the limitations of current diagnostics.”
“The Clinical Advisory Board is the perfect place to pull apart and validate the technology and ensure that it’s fit for purpose and ultimately has medical buy-in and acceptance,” said Professor Andreas Fouras.
4Dx team commenced in-human studies of their 4DxV four-dimensional x-ray technology in three hospitals in the US and expect FDA approval for their software by the end of 2016.